- Home
- ALXO vs ORIQ Comparison
ALXO vs ORIQ Comparison
Compare ALXO & ORIQ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ALXO
- ORIQ
- Stock Information
- Founded
- ALXO 2015
- ORIQ 2024
- Country
- ALXO United States
- ORIQ Singapore
- Employees
- ALXO N/A
- ORIQ N/A
- Industry
- ALXO Biotechnology: Pharmaceutical Preparations
- ORIQ
- Sector
- ALXO Health Care
- ORIQ
- Exchange
- ALXO Nasdaq
- ORIQ Nasdaq
- Market Cap
- ALXO 93.7M
- ORIQ 87.2M
- IPO Year
- ALXO 2020
- ORIQ 2025
- Fundamental
- Price
- ALXO $1.26
- ORIQ $10.19
- Analyst Decision
- ALXO Strong Buy
- ORIQ
- Analyst Count
- ALXO 6
- ORIQ 0
- Target Price
- ALXO $3.30
- ORIQ N/A
- AVG Volume (30 Days)
- ALXO 424.8K
- ORIQ 18.5K
- Earning Date
- ALXO 11-07-2025
- ORIQ 01-01-0001
- Dividend Yield
- ALXO N/A
- ORIQ N/A
- EPS Growth
- ALXO N/A
- ORIQ N/A
- EPS
- ALXO N/A
- ORIQ N/A
- Revenue
- ALXO N/A
- ORIQ N/A
- Revenue This Year
- ALXO N/A
- ORIQ N/A
- Revenue Next Year
- ALXO N/A
- ORIQ N/A
- P/E Ratio
- ALXO N/A
- ORIQ N/A
- Revenue Growth
- ALXO N/A
- ORIQ N/A
- 52 Week Low
- ALXO $0.40
- ORIQ $9.98
- 52 Week High
- ALXO $2.27
- ORIQ $10.15
- Technical
- Relative Strength Index (RSI)
- ALXO 38.76
- ORIQ N/A
- Support Level
- ALXO $1.49
- ORIQ N/A
- Resistance Level
- ALXO $1.64
- ORIQ N/A
- Average True Range (ATR)
- ALXO 0.14
- ORIQ 0.00
- MACD
- ALXO -0.05
- ORIQ 0.00
- Stochastic Oscillator
- ALXO 4.13
- ORIQ 0.00
About ALXO ALX Oncology Holdings Inc.
ALX Oncology Holdings Inc is a clinical-stage immuno-oncology company focused on helping patients fight cancer by developing a pipeline of product candidates based on expertise in protein engineering and oncology led by the CD47 blocker, evorpacept, currently in phase 1 and 2 clinical trials. Cancer cells leverage CD47, a cell surface protein, as a don't eat me signal to evade detection by the immune system. The company is developing a next-generation checkpoint inhibitor designed to have a high affinity for CD47 and to avoid the limitations caused by hematologic toxicities inherent in other CD47 blocking approaches.
About ORIQ Origin Investment Corp I Ordinary Shares
Origin Investment Corp I is a blank check company.